Company / Shareholders' Equity
Altimmune, Inc. Shareholders' Equity History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$224.9M
FY2025
5-year range
$185.3M / $225.9M
FY2021-FY2025
Trend
+15.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from $3M in FY2011 to $226M in FY2021.
Based on SEC 10-K filings.
$225M in FY2025 with a 5-year CAGR of +37.6%.
Improved from $185M to $225M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +4.1%
- 5-Year CAGR
- +37.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +37.6%, indicating consistent growth.
- In FY2025, shareholders' equity increased 15.9% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
- Lowest shareholders' equity in the period was in FY2011.
Company context
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $224.9M | +15.9% |
| FY2024 | $194.1M | +4.8% |
| FY2023 | $185.3M | -7.0% |
| FY2022 | $199.1M | -11.8% |
| FY2021 | $225.9M | +396.2% |
| FY2020 | $45.5M | -5.8% |
| FY2019 | $48.3M | +22.6% |
| FY2018 | $39.4M | +22.3% |
| FY2017 | $32.2M | +921.7% |
| FY2011 | $3.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026